NGM Biopharmaceuticals Executive Compensation (FY22)
NGM · Executive and director compensation, fiscal 2022 only
The NGM Biopharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of September 7, 2026Latest filing (8-K): May 12, 2023
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
120 figures on this page: 118 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
Frequently asked questions
Answers drawn from the data on this page.
Who is NGM Biopharmaceuticals' chief executive and what were they paid?
Total compensation for David Woodhouse, Chief Executive Officer, came to $5,933,500 in fiscal 2022.
What was NGM Biopharmaceuticals' say-on-pay result?
Shareholders recorded 97.7% support for the say-on-pay proposal at the meeting held May 10, 2023 for fiscal 2022.
Which companies are in NGM Biopharmaceuticals' peer group?
The disclosed peer group includes Alector, Inc., Allakos Inc., Allogene Therapeutics, Inc., AnaptysBio, Inc. and Apellis Pharmaceuticals, Inc., among others.
What is NGM Biopharmaceuticals' chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2022 is 24:1, against median employee compensation of $251,078.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
David Woodhouse Chief Executive Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Siobhan Nolan Mangini President and Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Hsiao Lieu Executive Vice President and Chief Medical Officer | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Jin-Long Chen Founder and Chief Scientific Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Valerie Pierce Senior Vice President, General Counsel, Chief Compliance Officer and Secretary | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2022
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| David J. Woodhouse | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Hsiao D. Lieu | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Hsiao D. Lieu | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Jin-Long Chen | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Siobhan Nolan Mangini | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Siobhan Nolan Mangini | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Valerie Pierce | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2022 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| David Woodhouse | Option | ◇ | — | ◇ | 3/2/2032 |
| Option | ◇ | — | ◇ | 3/16/2031 | |
| Siobhan Nolan Mangini | Option | ◇ | — | ◇ | 3/2/2032 |
| Option | ◇ | — | ◇ | 3/16/2031 | |
| Option | ◇ | — | ◇ | 6/30/2032 | |
| Hsiao Lieu | Option | ◇ | — | ◇ | 3/2/2032 |
| Option | ◇ | — | ◇ | 3/16/2031 | |
| Option | ◇ | — | ◇ | 11/3/2032 | |
| Valerie Pierce | Option | ◇ | — | ◇ | 3/2/2032 |
| Option | ◇ | — | ◇ | 3/16/2031 | |
| Jin-Long Chen | Option | ◇ | — | ◇ | 3/16/2031 |
| Option | ◇ | — | ◇ | 3/2/2032 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2022
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
William J. Rieflin Board chair | ◇ | — | — | — | — | ◇ | ◇ |
Shelly D. Guyer | ◇ | — | ◇ | — | — | — | ◇ |
David V. Goeddel, Ph.D Lead independent director | ◇ | — | ◇ | — | — | — | ◇ |
Suzanne Sawochka Hooper | ◇ | — | ◇ | — | — | — | ◇ |
Carole Ho, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Roger M. Perlmutter, M.D., Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Mark Leschly | ◇ | — | — | — | — | — | ◇ |
David J. Woodhouse, Ph.D and Jin-Long Chen, Ph.D served on the board in fiscal 2022 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2022
- Alector, Inc. ALEC
- Allakos Inc. ALLK
- Allogene Therapeutics, Inc. ALLO
- AnaptysBio, Inc. ANAB
- Apellis Pharmaceuticals, Inc. APLS
- Arcturus Therapeutics Holdings, Inc. ARCT
- Arcus Biosciences, Inc. RCUS
- Atara Biotherapeutics, Inc. ATRA
- Cytokinetics, Incorporated CYTK
- CytomX Therapeutics, Inc. CTMX
- Denali Therapeutics Inc. DNLI
- Dicerna Pharmaceuticals, Inc. symbol not shown
- Editas Medicine, Inc. EDIT
- Forma Therapeutics Holdings, Inc. symbol not shown
- Gossamer Bio, Inc. GOSS
- Kodiak Sciences Inc. KOD
- Madrigal Pharmaceuticals, Inc. MDGL
- Replimune Group, Inc. REPL
- Rubius Therapeutics, Inc. symbol not shown
- Scholar Rock Holding Corporation SRRK
- Turning Point Therapeutics, Inc. symbol not shown
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2022 | May 10, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 18, 2022 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
What this page does not include
Everything above is a fact NGM Biopharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where NGM Biopharmaceuticals sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
120 figures on this page: 118 cited to the filing that reported them, 2 calculated from figures it prints.
118 cited to the filing
2 calculated from the filing
Documents cited
- 0001193125-23-143465
- 0001628280-23-009712CEO Pay Ratio · DIRECTOR COMPENSATION · Grants of Plan-Based Awards · Outstanding Equity Awards at December 31, 2022 · and 1 more section
- 0001193125-22-158629
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “NGM Biopharmaceuticals executive compensation, FY2022.” https://intel.velarion.ai/comp/NGM (accessed 2026).
Short form: data: Velarion
The NGM Biopharmaceuticals brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about NGM Biopharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers NGM Biopharmaceuticals discloses
The companies named in NGM's own disclosed peer group.
Alector, Inc.Allakos Inc.Allogene Therapeutics, Inc.AnaptysBio, Inc.Apellis Pharmaceuticals, Inc.Arcturus Therapeutics Holdings, Inc.Arcus Biosciences, Inc.Atara Biotherapeutics, Inc.Cytokinetics, IncorporatedDenali Therapeutics Inc.Editas Medicine, Inc.Gossamer Bio, Inc.Kodiak Sciences Inc.Madrigal Pharmaceuticals, Inc.Replimune Group, Inc.Scholar Rock Holding Corporation
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}